<DOC>
	<DOCNO>NCT00992173</DOCNO>
	<brief_summary>This multi-center , single arm trial two dose 18 mCi/kg Ultratrace iobenguane I 131 administered subject high-risk neuroblastoma . Iobenguane I 131 drug already use many child treat neuroblastoma , know shrink tumor , cause manageable side effect . When administer intravenously , Iobenguane I 131 accumulates neuroblastoma cancer cell cause die . In study investigator investigate use new form Iobenguane I 131 call Ultratrace iobenguane I 131 . This form expect deliver high amount radioactive I 131 neuroblastoma cell . The primary purpose study determine Ultratrace iobenguane I 131 use successfully treat high-risk neuroblastoma . The study also assess safety Ultratrace iobenguane I 131 give patient high-risk neuroblastoma .</brief_summary>
	<brief_title>Efficacy Safety Ultratrace™ Iobenguane I 131 Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Patients must meet follow inclusion criterion : 1 . Males females &gt; 12 month age 2 . Have diagnosis neuroblastoma either ( ) histologic verification neuroblastoma and/or ( b ) demonstration tumor cell bone marrow increase urinary catecholamine metabolites 3 . Have highrisk neuroblastoma relapsed/refractory disease time . 4 . MIBG avid disease demonstrate 131I 123I MIBG uptake tumor ≥ one site within 28 day prior study treatment intervention/therapy time MIBG scan study treatment . 5 . To eligible receive least one therapeutic dose , patient must adequate bank autologous stem cell define : PBSC : A minimum 2.0 x 106 viable CD34+ cells/kg ( purge unpurged ) ( see Section 10.4.15 ) 6 . Prior Therapy : 1 . Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . There limitation number prior chemotherapeutic regimen patient may receive . 2 . The last dose local palliative radiation must ≥ 14 day prior first therapeutic dose Ultratrace iobenguane I 131 . Any lesion treat local palliative radiation period include baseline target lesion evaluation . 3 . The last dose local palliative radiation 25 % marrow contain bone must ≥ 28 day prior first therapeutic dose Ultratrace iobenguane I 131 . A minimum 3 month require follow prior large field radiation therapy ( i.e . craniospinal therapy , total lung , &gt; 50 % marrow space ) . Note : Radiation therapy focal skullbased bony metastatic disease ( ) consider craniospinal therapy . 4 . The last dose myelosuppressive biologic ( e.g. , isotretinoin [ also know cisretinoic acid , Accutane® ] ) therapy must least 14 day administration first therapeutic dose Ultratrace iobenguane I 131 protocol . 5 . The last dose immunotherapy must least 28 day prior first therapeutic dose Ultratrace iobenguane I 131 . 6 . All cytokine hematopoietic growth factor must discontinue minimum 7 day prior first therapeutic dose Ultratrace iobenguane I 131or 14 day prior first therapeutic dose Ultratrace iobenguane I 131for longacting colony stimulate factor . 7 . Prior treatment 131IMIBG therapy must ≥12 month prior first therapeutic dose Ultratrace iobenguane I 131 . 8 . Administration Neuroblastoma therapeutic investigational medication device must ≥30 day prior dosimetry dose . 9 . Prior autologous stem cell infusion must ≥2 month prior study entry . The patient must recover toxicity 7 . Adequate Organ Function : 1 . Adequate bone marrow function requirement , include patient postmyeloablative therapy tumor involvement bone marrow 2 . Adequate renal , hepatic , cardiac , lung thyroid function Patients exclude follow condition observe : 1 . Pregnant , lactate female intent breast feed . Females childbearing potential must negative serum pregnancy test prior therapy . Males female reproductive age childbearing potential must use effective contraception define abstinence use IUD , oral contraceptive , barrier spermicide , hormonal implant duration participation . Sexually active female patient use oral contraception require use second form barrier birth control . All patient require use effective contraception 60 day follow last therapeutic dose Ultratrace iobenguane I 131 . 2 . Have disease major organ system would compromise ability withstand therapy . 3 . Receiving hemodialysis renal obstruction , would effect urinary excretion MIBG . 4 . Is platelet transfusion dependent 5 . Status postallogeneic hematopoietic stem cell transplant . 6 . Concomitant use medication inhibit uptake Ultratrace iobenguane I 131 . 7 . Have know allergy iobenguane , iodine SSKI . 8 . If patient and/or family physically psychologically unable cooperate radiation safety isolation imaging requirement ( sedation general anesthesia permit ) . 9 . Administered prior chemotherapy within 30 day study entry active malignancy ( neuroblastoma ) require additional treatment . 10 . Any condition , opinion investigator , may compromise safety compliance subject would preclude subject successful completion study . 11 . Patient unable receive least one 15 mCi/kg dose per dosimetry finding .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>MIBG</keyword>
	<keyword>Iobenguane</keyword>
</DOC>